John A. Zebala

Dr. Zebala is the architect of the company and its development strategy. During his 10+ year tenure with the company, Dr. Zebala established company direction and brought company drug assets from discovery and through Phase 1 and Phase 2 clinical trials. Dr. Zebala was directly responsible for successfully opening Investigational New Drug (IND) applications with the FDA; navigating pre-IND and other post-IND Type B meetings with the FDA; designing and managing the toxicology studies that supported IND applications; directing the manufacture and supply of drug in compliance with current Good Manufacturing Practice; authoring and implementing Phase 1 and 2 clinical trial protocols and securing Institutional Review Board approval; securing National Institutes of Health (NIH) funding as Principal Investigator on over $20 million in grants to the company; and securing deal discussions over these assets with several pharmaceutical companies. He is an inventor on over 20 issued US patents, and author to more than 25 peer reviewed scientific articles. Dr. Zebala has served as an invited reviewer on numerous NIH study sections and review groups concerning drug development and therapeutics. He is the recipient of several research prizes and scientific awards including the David Roger Health Policy Colloquium Award from the Weill Cornell Medical College in 2011. Dr. Zebala was an invited speaker by the National Cancer Institute at investor forums.